Synergistic anti-CD47 therapy for hematologic cancers
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
1. A method for depleting hematologic cancer cells in a subject, the method comprising:
administering to the subject, at a dose that achieves depletion of hematologic cancer cells, a synergistic combination of antibodies comprising a first soluble antibody that binds to CD47 and prevents the binding of CD47 with SIRPα, and a second antibody that selectively binds CD20.
2. The method of claim 1 , wherein one or both of said antibodies is conjugated to a cytotoxic agent.
3. The method of claim 2 , wherein said cytotoxic agent is selected from the group consisting of a radioactive isotope, a chemotherapeutic agent and a toxin.
4. The method of claim 1 , wherein the hematologic cancer cells are non-Hodgkin's lymphoma (NHL) cells.
5. The method of claim 4 , wherein the NHL cells are diffuse large B cell lymphoma cells.
6. A method for depleting hematologic cancer cells in a subject, the method comprising:
administering to the subject, at a dose that achieves depletion of hematologic cancer cells, a soluble bispecific antibody selective for CD47 and CD20 that binds to CD47 and prevents the binding of CD47 with SIRPα, and that selectively binds CD20.
7. A method for depleting diffuse large B cell lymphoma cells in a subject, the method comprising:
administering to the subject a synergistic combination of soluble antibodies comprising a first antibody that binds to CD47 and prevents the binding of CD47 with SIRPα, and a second antibody that selectively binds CD20;
wherein diffuse large B cell lymphoma cells are depleted or eliminated from the subject.
8. The method of claim 6 , wherein the hematologic cancer cells are diffuse large B cell lymphoma cells.